RELIEF THERAPEUTICS Holding (RLF) AI Stock Analysis

• Market Cap: CHF416.60M
• Dividend Yield: N/A
• Average Volume (3M): 36.57K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.92
• Revenue Growth: -52.81%
• EPS Growth: 63.16%
• Country: CH
• Employees: 31
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.36
• Shares Outstanding: 154,102,450
• 10 Day Avg. Volume: 19,929
• 30 Day Avg. Volume: 36,567
• PEG Ratio: 0.04
• Price to Book (P/B): 1.44
• Price to Sales (P/S): 6.27
• P/FCF Ratio: -17.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: CHF3.00 ▲(57.89% Upside)

The overall stock score is primarily impacted by the company's weak financial performance, characterized by ongoing losses and negative cash flow. Technical analysis provides a slightly more positive outlook with neutral momentum indicators, but valuation remains a concern due to the negative P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

The significant revenue growth indicates increasing demand for RLF's products, suggesting successful market penetration and potential for future expansion.

Gross Profit Margin

An improved gross profit margin reflects better cost management and pricing strategies, enhancing long-term profitability potential.

Equity Position

A strong equity position provides financial stability and flexibility, allowing RLF to invest in growth opportunities without excessive leverage.

Negative Factors

Negative Cash Flow

Negative cash flow indicates challenges in generating sufficient cash from operations, potentially limiting RLF's ability to fund growth and meet obligations.

Net Profitability

Continued net losses highlight operational inefficiencies and the need for RLF to improve cost control and revenue generation to achieve sustainable profitability.

Operational Challenges

Negative EBIT and EBITDA margins suggest ongoing operational inefficiencies, which may hinder RLF's ability to achieve long-term financial sustainability.

RELIEF THERAPEUTICS Holding Business Overview & Revenue Model

Company Description

RELIEF THERAPEUTICS Holding (RLF) is a biotechnology company focused on the development and commercialization of innovative therapies for patients suffering from various unmet medical needs. The company operates primarily in the biotechnology sector, with a strong emphasis on developing treatments for conditions such as respiratory diseases, neurological disorders, and metabolic disorders. RLF's core products include innovative drug candidates that target specific pathways associated with these diseases, aiming to improve patient outcomes and quality of life.

How the Company Makes Money

RELIEF THERAPEUTICS generates revenue through multiple channels, including the development and licensing of its drug candidates to pharmaceutical companies, which may involve milestone payments and royalties on sales. The company may also engage in strategic partnerships and collaborations with other biotech firms to co-develop therapies, sharing both costs and profits. Additionally, RLF may receive funding through grants and public offerings, particularly for its research initiatives aimed at advancing its product pipeline. These revenue streams are supplemented by potential future sales of approved therapies in the market.

RELIEF THERAPEUTICS Holding Financial Statement Overview

Summary

RELIEF THERAPEUTICS Holding shows revenue growth and a strong equity position, but ongoing losses and negative free cash flow highlight profitability and cash management challenges. The company has potential for improvement but faces significant operational hurdles.

Income Statement

The company shows some improvement in revenue, with a 39.5% growth from the previous year. Gross profit margin improved to 69.4%, but net profit remains negative, impacting the overall profitability. EBIT and EBITDA margins are negative, indicating operational challenges and inefficiencies.

Balance Sheet

The debt-to-equity ratio is low at 0.06, suggesting limited leverage. However, the return on equity is negative due to continued net losses. The equity ratio is strong at 68.9%, indicating financial stability with a substantial equity base.

Cash Flow

Free cash flow remains negative, but it has improved compared to the previous year. The operating cash flow to net income ratio is less relevant due to negative net income. The company needs to improve cash generation to support operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.05M	8.42M	6.03M	6.08M	3.32M	0.00
Gross Profit	-1.18M	5.84M	4.11M	4.83M	-8.59M	0.00
EBITDA	-18.22M	-16.73M	-108.04M	-50.26M	-32.69M	-6.09M
Net Income	-17.04M	-17.12M	-98.18M	-50.79M	-34.70M	-7.83M
Balance Sheet
Total Assets	47.99M	53.22M	76.39M	188.80M	251.62M	78.05M
Cash, Cash Equivalents and Short-Term Investments	12.50M	15.08M	14.56M	19.24M	44.76M	43.15M
Total Debt	1.90M	2.14M	2.96M	4.34M	4.26M	891.00K
Total Liabilities	15.35M	16.56M	24.16M	43.38M	70.09M	11.00M
Stockholders Equity	32.63M	36.66M	52.23M	145.42M	181.53M	67.04M
Cash Flow
Free Cash Flow	-3.43M	-3.09M	-18.06M	-24.63M	-49.42M	-18.23M
Operating Cash Flow	-3.40M	-2.92M	-17.61M	-24.11M	-35.71M	-18.23M
Investing Cash Flow	5.59M	4.40M	8.70M	-8.02M	-30.27M	3.00M
Financing Cash Flow	-303.00K	-862.00K	4.05M	6.42M	67.69M	58.18M

RELIEF THERAPEUTICS Holding Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:RLF, the sentiment is Negative. The current price of 1.9 is below the 20-day moving average (MA) of 2.60, below the 50-day MA of 2.76, and below the 200-day MA of 2.58, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 45.42 is Neutral, neither overbought nor oversold. The STOCH value of 62.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:RLF.

RELIEF THERAPEUTICS Holding Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NWRN	74 Outperform	CHF456.11M	19.75	―	―	744.64%	―
BSLN	73 Outperform	CHF663.84M	9.23	―	―	58.51%	―
MOLN	54 Neutral	CHF142.32M	-2.11	-49.86%	―	-100.00%	14.45%
SANN	53 Neutral	CHF172.40M	-2.51	-301.13%	―	-56.85%	-186.55%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IDIA	44 Neutral	CHF1.13B	-6.62	―	―	229.23%	63.47%
RLF	43 Neutral	CHF416.60M	-2.04	-40.91%	―	-52.81%	63.16%

RELIEF THERAPEUTICS Holding Corporate Events

Relief Therapeutics and NeuroX Announce Strategic Business Combination

Relief Therapeutics Holding SA announced a joint presentation with NeuroX Group SA ahead of their anticipated business combination, expected to close in mid-December 2025. The combined entity projects significant revenue growth, aiming for over CHF 40 million in 2027 and exceeding CHF 200 million by 2031, with a normative EBITDA margin of approximately 55% by 2028. This growth is driven by the adoption of NeuroX’s digital neurotherapeutics suite, following the consolidation of MindMaze assets, positioning the company for substantial market expansion.

Relief Therapeutics to Merge with NeuroX, Forming MindMaze Therapeutics

Relief Therapeutics Holding SA announced that its shareholders have approved a business combination with NeuroX Group SA, creating a publicly listed digital neurotherapeutics company. The merger, expected to close in December 2025, will see the company renamed MindMaze Therapeutics Holding SA and the integration of NeuroX’s brain health platform with Relief’s biopharmaceutical portfolio. This strategic move is anticipated to strengthen the company’s position in the neurotherapeutics industry, with new leadership appointments and a focus on expanding their R&D pipeline for neurological conditions.

Relief Therapeutics Reports Positive Bioequivalence Study Results for PKU Treatment

Relief Therapeutics announced positive results from a pivotal bioequivalence study of RLF-OD032, a liquid formulation of sapropterin dihydrochloride for treating phenylketonuria (PKU). The study confirmed that RLF-OD032 is bioequivalent to KUVAN® Powder, supporting a planned NDA submission in early 2026. This innovation offers a patient-friendly alternative by significantly reducing the volume of medication required, potentially improving adherence and quality of life for PKU patients. If approved, RLF-OD032 would be the first ready-to-use liquid sapropterin formulation, with patent protection extending through at least 2043.

Relief Therapeutics Plans Strategic Merger with NeuroX Group

Relief Therapeutics has announced an extraordinary general meeting to seek shareholder approval for a business combination with NeuroX Group SA. The meeting will address proposals including a capital increase and board member elections, aiming to rename the combined entity MindMaze Therapeutics Holding SA. This strategic move is expected to enhance Relief’s position in the biopharmaceutical industry by integrating NeuroX’s advanced neurotherapeutic technologies, potentially benefiting stakeholders through expanded treatment options and market reach.

Relief Therapeutics and NeuroX Merge to Form AI-Driven Health Tech Leader

Relief Therapeutics and NeuroX have signed a definitive agreement to merge, creating a publicly listed AI-driven health tech company named MindMaze Therapeutics Holding SA. This merger positions the company as a leader in neurotherapeutic solutions, leveraging a robust commercialization network and a proprietary neuro-data engine for scalable precision medicine. The transaction, expected to close in December 2025, involves a significant equity exchange and aims to expand the company’s market presence and investor appeal, with plans to enhance visibility in the U.S. market.